See pp 288, 298 In the coronary circulation in particular, recognition of the role of thrombosis in acute myocardial infarction is largely responsible for the recent development and clinical application of thrombolytic therapy. Because invasive angiographic assessment is not logistically feasible or ethically acceptable before the initiation of thrombolytic therapy in most patients with evolving infarction, the diagnosis is made without firm evidence for the presence of an acute thrombotic coronary process, let alone unequivocal identification of the involved vessel: The localization of a "culprit" lesion in' acute infarction rests largely on inferential electrocardiographic, echocardiographic, or scintigraphic data.
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The lack of a simple, relatively noninvasive method for identifying an acute atherothrombotic stenosis or occlusion is a notable deficiency in current cardiovascular practice. Inaccurate diagnosis, ineffective therapeutic response, and reocclusion or restenosis after initially successful therapy are all potential pitfalls of current approaches to patients with suspected acute occlusive arterial syndromes; improvement in diagnosis and management would be facilitated by an efficient and specific method for defining noninvasively and unequivocally the status of the culprit vascular lesion.
The majority of studies and methods developed to image thrombi involve the use of radionuclide imaging agents. The Over the past 20 years, a number of approaches have been used to minimize these problems and have met with variable degrees of success. Three principal elements of the thrombus have been chosen as targets for labeling: fibrin, platelets, and fibrinolytic molecules. Antibodies targeted to epitopes on these components or directly labeled components have been used. After the experience with radiolabeled fibrinogen, the field advanced only with the development of monoclonal antibody technology for the preparation of antibodies that distinguish epitopes on fibrin from those on fibrinogen.56 Antibodies to platelets incorporated in thrombi have also been used, including an antibody to the fibrinogen receptor glycoprotein IIb/IIIa,7 one to an antigen expressed only on activated platelets (PADGEM),8 and one to radiolabeled autologous platelets directly. 9 The first two methods suffer primarily from being able to detect only fresh thrombi, whereas in the last-named method, radiolabeled erythrocytes must be used concomitantly to reduce the blood pool background. Inasmuch as plasminogen binds to fibrin through its kringle domains, one group has attempted to use radiolabeled plasminogen as an imaging agent.10 Others have used radiolabeled streptokinase"l and urokinase,12 arguing that their affinity for plasminogen bound to the thrombus will facilitate uptake of the labeled molecule. These studies, again, have suffered primarily from lack of adequate sensitivity to detect small thrombi.
Alternative approaches for the detection by radionuclide scintigraphy of coronary occlusion in particular involves the recent application of perfusion imaging agents such as [99mTc]-sestamibil3,14 or the more short-lived compound [99mTc]-teboroxime. 15 These methods suffer primarily from the lack of direct imaging of thrombi and the requirement for poor collateralization to ensure sufficiently reduced perfusion for detection; they do, however, provide information about the functional importance of an occlusive process.
In this issue of Circulation, two groups present work on thrombus imaging with two newly developed methodologies. Cerqueira and colleagues16 used a murine monoclonal antibody, T2G1s, which recognizes fibrin's aminoterminal ,3-chain heptapeptide selectively. They improved on earlier studies by using a similar monoclonal, 59D8 [1311]-DLT-PPACK-t-PA manifested strikingly elevated clot-to-blood ratios in the carotid, pulmonary, and coronary vessels of 37, 42, and 137, respectively. Administration 10 minutes to 1 hour after clot formation, however, led to reduced but respectable ratios of 28, 8, and 18, respectively, for the carotid, pulmonary, and femoral vessels. No ratio was reported with administration of label after clot formation for coronary vessels. Single-photon emission computed tomography (SPECT) imaging of carotid clots was successful with infusion of label during clot formation and of femoral clots with infusion of label after clot formation. The success of this method for imaging clots in relatively small vessels (despite the use of [1311] ) likely accounted for the high clot-to-blood ratios achieved with the highly specific and clot-avid t-PA derivative. That the SPECT technique enhances the sensitivity of detection follows from the fact that SPECT acquisition enhances contrast resolution (i.e., it improves definition of target versus background activity). However, this improvement in contrast resolution occurs at the expense of spatial resolution and, therefore, may not be as useful when applied to imaging thrombi in the coronary circulation.
This innovative approach is biologically sound: blocking the active site of t-PA with PPACK prevents dissolution of the clot by the labeled plasminogen activator which, while therapeutically beneficial, would limit its diagnostic potential by dissolving the fibrin substrate to which it must bind for imaging. Data are also provided that indicate the lack of impairment of fibrinolysis by relatively low absolute concentrations of this inactivated and potentially competitive derivative of t-PA. The use of the residualizing label DLT facilitates exclusion of potential metabolic, competitive proteolytic degradation fragments of [`311]-t-PA from the vascular compartment that would decrease the signal-to-noise (i.e., clot-toblood) ratio. Several important shortcomings are apparent with the use of this agent. Less [1311]-DLT-PPACK-t-PA bound to clots with increasing age, likely as a consequence of diffusion limitation into an increasing crosslinked fibrin matrix. Clot-to-blood ratios were greatest when imaging agent was added during clot formation. The specificity of the agent for thrombi may be less than ideal, given the propensity of t-PA to bind to specific surface receptors on the endothelium.2'-23 
